Benjamin P. Levy

A panel of thoracic medical oncologists discuss the first-line treatment options for patients with EGFR-mutant advanced non–small cell lung cancer.

Comprehensive insights on FLAURA2, which looked at osimertinib and chemotherapy in the front line for patients with EGFR-mutant NSCLC.

The expert panel closes its discussion with advice for community physicians and discusses the future treatment landscape for advanced non–small cell lung cancer.

The panel reacts to the MARIPOSA trial, which looked at amivantamab, lazertinib, and chemotherapy in the front line in patients with EGFR-mutant non–small cell lung cancer.

Joshua K. Sabari, MD, reviews data from the MARIPOSA-2 trial and discusses treatment options in the second line and beyond for patients with EGFR-mutant non–small cell lung cancer.

The panel discusses the use of antibody-drug conjugates for patients with EGFR-mutant non–small cell lung cancer, with a focus on the HERTHENA-Lung01 and TROPION-Lung05 studies.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Panelists discuss how the evolving treatment landscape for HER2-overexpressing NSCLC, particularly with the introduction of trastuzumab deruxtecan, influences therapeutic strategies and decision-making based on recent clinical trial data.

Panelists discuss how ongoing trials may reshape the treatment landscape for HER2-altered NSCLC, particularly regarding the roles of ADCs and TKIs in managing both HER2-mutated and HER2-overexpressing NSCLC.

Panelists discuss how thoracic oncologists are adapting to a rapidly evolving treatment landscape for lung cancer, focusing on the integration of novel therapies and the importance of biomarker-driven approaches in patient care.